185株对青霉素敏感和耐药的肺炎球菌对新型口服青霉烯类药物WY-49605（SUN/SY 5555）的体外药敏情况，并与它们对青霉素G、阿莫西林、阿莫西林-克拉维酸、头孢克肟、头孢克洛、头孢泊肟、头孢呋辛和头孢地尼的药敏情况进行比较。
In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir.
作者信息
Spangler S K, Jacobs M R, Appelbaum P C
机构信息
Department of Pathology (Clinical Microbiology), Hershey Medical Center, Pennsylvania 17033.
出版信息
Antimicrob Agents Chemother. 1994 Dec;38(12):2902-4. doi: 10.1128/AAC.38.12.2902.
Abstract
In vitro susceptibility of 185 penicillin-susceptible and -resistant pneumococci to WY-49605, a new oral penem, was compared with susceptibility to penicillin G, amoxicillin with and without clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. WY-49605 yielded MICs for 50 and 90% of the strains tested (MIC50 and MIC90, respectively) of 0.03 and 0.06, 0.125 and 0.5, and 0.5 and 1.0 micrograms/ml, respectively, against penicillin-susceptible, intermediately resistant, and fully resistant strains, respectively. The MIC50 and MIC90 for both amoxicillin and amoxicillin-clavulanate were identical and approximately 1 doubling dilution higher than those for WY-49605 and were < or = 0.06 and 0.125, 0.25 and 1.0, and 1.0 and 1.0 micrograms/ml, respectively. Cephalosporin MIC90s were all significantly higher than those of the latter three compounds for intermediately resistant and fully resistant strains.
摘要
将185株对青霉素敏感和耐药的肺炎球菌对新型口服青霉烯类药物WY - 49605的体外敏感性，与对青霉素G、含和不含克拉维酸的阿莫西林、头孢克肟、头孢克洛、头孢泊肟酯、头孢呋辛和头孢地尼的敏感性进行比较。WY - 49605对青霉素敏感、中度耐药和完全耐药菌株的50%和90%受试菌株（分别为MIC50和MIC90）的MIC值分别为0.03和0.06、0.125和0.5、0.5和1.0微克/毫升。阿莫西林和阿莫西林 - 克拉维酸的MIC50和MIC90相同，比WY - 49605的MIC值高约1倍稀释度，分别为≤0.06和0.125、0.25和1.0、1.0和1.0微克/毫升。对于中度耐药和完全耐药菌株，头孢菌素的MIC90均显著高于后三种化合物。
相似文献
1
In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir.185株对青霉素敏感和耐药的肺炎球菌对新型口服青霉烯类药物WY-49605（SUN/SY 5555）的体外药敏情况，并与它们对青霉素G、阿莫西林、阿莫西林-克拉维酸、头孢克肟、头孢克洛、头孢泊肟、头孢呋辛和头孢地尼的药敏情况进行比较。
Antimicrob Agents Chemother. 1994 Dec;38(12):2902-4. doi: 10.1128/AAC.38.12.2902.
2
In vitro susceptibility of 90 penicillin-susceptible and -resistant pneumococci to penicillin G, amoxicillin, amoxicillin/clavulanate, cefaclor, cefuroxime, cefpodoxime, cefixime and imipenem.90株对青霉素敏感及耐药的肺炎球菌对青霉素G、阿莫西林、阿莫西林/克拉维酸、头孢克洛、头孢呋辛、头孢泊肟、头孢克肟和亚胺培南的体外敏感性。
Folia Microbiol (Praha). 1998;43(1):68-70. doi: 10.1007/BF02815546.
3
Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria.WY-49605与阿莫西林、阿莫西林-克拉维酸、亚胺培南、环丙沙星、头孢克洛、头孢泊肟、头孢呋辛、克林霉素及甲硝唑对384株厌氧菌的活性比较。
Antimicrob Agents Chemother. 1994 Nov;38(11):2599-604. doi: 10.1128/AAC.38.11.2599.
4
Comparative in-vitro activity of cefdinir against multiresistant Haemophilus influenzae.头孢地尼对多重耐药流感嗜血杆菌的体外活性比较
J Antimicrob Chemother. 1994 Jul;34(1):161-4. doi: 10.1093/jac/34.1.161.
5
Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.头孢泊肟与头孢克肟、头孢地尼、头孢他美、头孢布烯、氯碳头孢、头孢丙烯、BAY 3522、头孢呋辛、头孢克洛和头孢羟氨苄的抗菌活性比较。
Infection. 1991 Sep-Oct;19(5):353-62. doi: 10.1007/BF01645369.
6
Comparative antimicrobial activities of the penem WY-49605 (SUN5555) against recent clinical isolates from five U.S. medical centers.青霉烯类药物WY-49605（SUN5555）对来自美国五个医疗中心的近期临床分离株的抗菌活性比较
Antimicrob Agents Chemother. 1995 Jul;39(7):1591-5. doi: 10.1128/AAC.39.7.1591.
7
In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.21种β-内酰胺类抗生素对青霉素敏感和耐药肺炎链球菌的体外活性
J Antimicrob Chemother. 1998 Mar;41(3):381-5. doi: 10.1093/jac/41.3.381.
8
In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.口服亚胺甲氧基氨噻唑基头孢菌素R-3746的体外活性
Antimicrob Agents Chemother. 1988 May;32(5):671-7. doi: 10.1128/AAC.32.5.671.
9
Activities of oral and parenteral agents against penicillin-susceptible and -resistant pneumococci.口服及肠胃外给药制剂对青霉素敏感及耐药肺炎球菌的活性。
Antimicrob Agents Chemother. 1995 Jul;39(7):1499-504. doi: 10.1128/AAC.39.7.1499.
10
In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria.头孢克肟（FK027、FR17027、CL284635）的体外评估：对近期临床分离株的抗菌谱、抗菌活性比较、β-内酰胺酶稳定性及初步药敏试验标准
Diagn Microbiol Infect Dis. 1986 Jul;5(2):151-62. doi: 10.1016/0732-8893(86)90117-3.
引用本文的文献
1
Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.头孢地尼：用于治疗轻至中度细菌感染的综述。
Drugs. 2004;64(13):1433-64. doi: 10.2165/00003495-200464130-00004.
2
Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 250 invasive Streptococcus pneumoniae isolates from France.法罗培南与其他11种抗菌药物对来自法国的250株侵袭性肺炎链球菌分离株的体外活性比较
Eur J Clin Microbiol Infect Dis. 2003 Sep;22(9):561-5. doi: 10.1007/s10096-003-0990-7. Epub 2003 Aug 27.
3
Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.口服β-内酰胺类药物法罗培南对美国近期分离出的肺炎链球菌、流感嗜血杆菌和卡他莫拉菌的活性。
Antimicrob Agents Chemother. 2002 Feb;46(2):550-5. doi: 10.1128/AAC.46.2.550-555.2002.
4
Streptococcus pneumoniae: Activity of Newer Agents Against Penicillin-Resistant Strains.肺炎链球菌：新型药物对青霉素耐药菌株的活性
Curr Infect Dis Rep. 1999 Apr;1(1):13-21. doi: 10.1007/s11908-999-0004-8.
5
Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents.将青霉素敏感及耐药、红霉素敏感及耐药的肺炎球菌对新型酮内酯类药物HMR 3647（RU 66647）的敏感性与对其他17种药物的敏感性进行比较。
Antimicrob Agents Chemother. 1998 Mar;42(3):624-30. doi: 10.1128/AAC.42.3.624.
6
Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci.与其他六种药物相比，头孢噻肟对12株青霉素敏感和耐药肺炎球菌的抗生素后效应。
Antimicrob Agents Chemother. 1997 Oct;41(10):2173-6. doi: 10.1128/AAC.41.10.2173.
7
Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640.新型口服碳青霉烯类药物DZ-2640的母体化合物DU-6681a的抗菌活性
Antimicrob Agents Chemother. 1997 Jun;41(6):1260-8. doi: 10.1128/AAC.41.6.1260.
8
Susceptibilities of 228 penicillin- and erythromycin-susceptible and -resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents.228株对青霉素和红霉素敏感及耐药的肺炎球菌对新型酮内酯类药物RU 64004的敏感性，与对其他16种药物的敏感性比较。
Antimicrob Agents Chemother. 1997 May;41(5):1033-6. doi: 10.1128/AAC.41.5.1033.
9
MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents.将GV 118819X（三苯菌素）与其他药物的抗肺炎球菌活性进行的最低抑菌浓度（MIC）和杀菌动力学研究。
Antimicrob Agents Chemother. 1997 Jan;41(1):148-55. doi: 10.1128/AAC.41.1.148.
10
Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.RPR 106972（一种新型口服链阳菌素）、头孢妥仑（一种新型口服头孢菌素）、两种新型恶唑烷酮（U-100592和U-100766）以及其他口服和胃肠外用药对203株青霉素敏感和耐药肺炎球菌的活性。
Antimicrob Agents Chemother. 1996 Feb;40(2):481-4. doi: 10.1128/AAC.40.2.481.
本文引用的文献
1
Studies on penem antibiotics. II. In vitro activity of SUN5555, a new oral penem.青霉烯类抗生素的研究。II. 新型口服青霉烯类药物SUN5555的体外活性
J Antibiot (Tokyo). 1989 Jun;42(6):977-88. doi: 10.7164/antibiotics.42.977.
2
Susceptibility of anaerobic bacteria to ALP 201.厌氧细菌对ALP 201的敏感性。
Antimicrob Agents Chemother. 1989 Dec;33(12):2137-9. doi: 10.1128/AAC.33.12.2137.
3
Comparative in vitro activity of the new oral penem ALP-201 against aerobic and anaerobic bacteria.新型口服青霉烯类药物ALP-201对需氧菌和厌氧菌的体外活性比较
Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):919-24. doi: 10.1007/BF01963784.
4
Comparative antibacterial activity of the penem ALP 201.青霉烯类药物ALP 201的抗菌活性比较
Chemotherapy. 1991;37(6):413-9. doi: 10.1159/000238888.
5
Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990).西班牙巴塞罗那贝尔维奇医院肺炎链球菌临床分离株的抗菌药物耐药性趋势（1979 - 1990年）
Clin Infect Dis. 1992 Jul;15(1):99-105. doi: 10.1093/clinids/15.1.99.
6
Antimicrobial resistance in Streptococcus pneumoniae: an overview.肺炎链球菌中的抗菌药物耐药性：概述
Clin Infect Dis. 1992 Jul;15(1):77-83. doi: 10.1093/clinids/15.1.77.
7
Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.耐多药肺炎链球菌所致感染的治疗与诊断
Clin Infect Dis. 1992 Jul;15(1):119-27. doi: 10.1093/clinids/15.1.119.
8
Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics.耐青霉素肺炎球菌对24种β-内酰胺类抗生素的敏感性降低。
J Antimicrob Chemother. 1992 Sep;30(3):279-88. doi: 10.1093/jac/30.3.279.
Zotero 插件